- Home
- KF vs IOBT Comparison
KF vs IOBT Comparison
Compare KF & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- IOBT
- Stock Information
- Founded
- KF 1984
- IOBT 2014
- Country
- KF United States
- IOBT Denmark
- Employees
- KF N/A
- IOBT N/A
- Industry
- KF Investment Managers
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- KF Finance
- IOBT Health Care
- Exchange
- KF Nasdaq
- IOBT Nasdaq
- Market Cap
- KF 116.7M
- IOBT 114.6M
- IPO Year
- KF N/A
- IOBT 2021
- Fundamental
- Price
- KF $30.58
- IOBT $1.62
- Analyst Decision
- KF
- IOBT Strong Buy
- Analyst Count
- KF 0
- IOBT 2
- Target Price
- KF N/A
- IOBT $8.00
- AVG Volume (30 Days)
- KF 18.4K
- IOBT 1.1M
- Earning Date
- KF 01-01-0001
- IOBT 11-11-2025
- Dividend Yield
- KF N/A
- IOBT N/A
- EPS Growth
- KF N/A
- IOBT N/A
- EPS
- KF N/A
- IOBT N/A
- Revenue
- KF N/A
- IOBT N/A
- Revenue This Year
- KF N/A
- IOBT N/A
- Revenue Next Year
- KF N/A
- IOBT N/A
- P/E Ratio
- KF N/A
- IOBT N/A
- Revenue Growth
- KF N/A
- IOBT N/A
- 52 Week Low
- KF $18.30
- IOBT $0.66
- 52 Week High
- KF $25.56
- IOBT $2.79
- Technical
- Relative Strength Index (RSI)
- KF 71.98
- IOBT 44.35
- Support Level
- KF $29.45
- IOBT $1.71
- Resistance Level
- KF $30.41
- IOBT $2.08
- Average True Range (ATR)
- KF 0.36
- IOBT 0.15
- MACD
- KF 0.26
- IOBT -0.01
- Stochastic Oscillator
- KF 99.57
- IOBT 16.36
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.